Onconetix, Inc. — Form S-1
Filed August 12, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
On July 29, 2026, Onconetix issued 37,812 shares of Series F Preferred Stock to an unnamed PIPE investor for $30.25M aggregate consideration ($30M via cancellation of prior commitment fees + $0.25M cash). The Series F is convertible into common stock at $0.9767/share, with this S-1 registering up to 100M shares for resale by Seven Knots LLC (sole holder). Company simultaneously entered a $750M ELOC facility with same investor, capped at 789,426 shares absent stockholder approval. Company had $5.4M cash as of August 10, 2026, with substantial going-concern doubt and accumulated deficit of $135.4M.
Why this rating
Financing is modest relative to company size; primarily debt restructuring (fees cancelled). Extreme dilution concern (100M new shares vs. 3.9M existing) but conversion-limited by 4.99% blocker and Nasdaq rules. Going-concern risk persists despite capital raise.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.